AIDS and Behavior

, Volume 5, Issue 4, pp 371–378 | Cite as

Prescription of and Adherence to Antiretroviral Therapy Among Women with AIDS

  • Paula Schuman
  • Suzanne E. Ohmit
  • Mardge Cohen
  • Henry S. Sacks
  • Jean Richardson
  • Mary Young
  • Ellie Schoenbaum
  • Anne Rompalo
  • Lytt Gardner


The benefits of antiretroviral therapy (ART) in reducing the risks of AIDS-associated morbidity and mortality are dependent on rigorous adherence to prescription. We assessed patient self-reported prescription of ART, adherence to prescribed medications, and factors related to prescription and adherence among participants in 2 cohort studies of HIV infection in women. Four hundred fifty-three HIV-seropositive women with advanced HIV disease were enrolled in this cross-sectional study and were interviewed between December 1996 and December 1997. Eighty-two percent of women reported ART prescription within the past 6 months; of these, 88% reported combination therapy and 60% use of protease inhibitors. Seventy-seven percent of women reporting ART prescription reported adherence with prescription in the prior 2 weeks either as frequently as prescribed or almost all the time (>75% of the time). Reported reasons for nonadherence included forgetting to take medication and unpleasant side effects. Women with CD4+ lymphocyte counts ≥200/mm3 at interview were more likely to report adherence, as were women with HIV viral load values below detectable limits. Depressive symptoms were prevalent among participants and were significantly associated with poorer adherence. Improvement in adherence may require increased diagnosis and treatment of these symptoms.

adherence antiretroviral therapy depression HIV seropositive HIV viral load 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Barkan, S. E., Melnick, S. L., Preston-Martin, S., Weber, K., Kalish, L. A., Miotti, P., Young, M., Greenblatt, R., Sacks, H., and Feldman, J. (1998). The Women's Interagency HIV study. Epidemiology, 9, 117–125.Google Scholar
  2. Bing, E. G., Kilbourne, A. M., Brooks, R. A., Lazarus, E. F., and Senak, M. (1999). Protease inhibitor use among a community sample of people with HIV disease. Journal of Acquired Immune Deficiency Syndrome, 20, 474–480.Google Scholar
  3. Celentano, D. D., Vlahov, D., Cohn, S., Shadle, V. M., Obasanjo, O., and Moore, R. D. (1998). Self-reported antiretroviral therapy in injection drug users. JAMA, 280, 544–546.Google Scholar
  4. Chesney, M. A., Ickovics, J., Hecht, F. M., Sikipa, G., and Rabkin, J. (1999). Adherence: A necessity for successful HIV combination therapy. AIDS, 13(Suppl. A), S271-S278.Google Scholar
  5. Clumeck, N., and DeWit, S. (2000). Update on highly active antiretroviral therapy: Progress and strategies. Biomedicine and Pharmacotherapy, 54, 7–12.Google Scholar
  6. Deeks, S. G., Smith, M., Holodney, M., and Kahn, J. O. (1997). HIV-1 protease inhibitors: A review for clinicians. JAMA, 277, 145–153.Google Scholar
  7. Detels, R., Munoz, A., McFarlane, G., Kingsley, L. A., Margolick, J. B., Giorgi, J., Schrager, L. K., and Phair, J. P. (1998). Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA, 280, 1497–1503.Google Scholar
  8. Dunbar-Jacob, J., Burke, L. E., and Puczynski, S. (1995). Clinical assessment and management of adhernce to medical regimens. In P. M. Nicassio and T. W. Smith (Eds.), Managing chronic illness: A biophychosocial perspective. Washington, DC: American Psychologicial Association.Google Scholar
  9. Eron, J. J., Yetzer, E. S., Ruane, P. J., Becker, S., Sawyer, G. A., Fisher, R. L., Tolson, J. M., and Shaefer, M. S. (2000). Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection. AIDS, 14, 671–681.Google Scholar
  10. Flexner, C. (1998). Drug therapy: HIV protease inhibitors. New England Journal of Medicine, 338, 1281–1292.Google Scholar
  11. Friedland, G. H., and Williams, A. (1999). Attaining higher goals in HIV treatment: The central importance of adherence. AIDS, 13(Suppl. 1), S61-S72.Google Scholar
  12. Gallant, J. E. (2000a). Strategies for long-term success in the treatment of HIV infection. JAMA, 283, 1329–1334.Google Scholar
  13. Gallant, J. E. (2000b). Drug Guide 2000: The antiretroviral agents. Posit Aware, 11, 30–31.Google Scholar
  14. Gordillo, V., del Amo, J., Soriano, V., and Gonzalez-Lahoz, J. (1999). Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS, 13, 1763–1769.Google Scholar
  15. Gourevitch, M. N., Wasserman, W., Panero, M. S., and Selwyn, P. A. (1996). Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program. Journal of Addictive Diseases, 15, 93–104.Google Scholar
  16. Hellinger, F. J. (1993). The use of health services by women with HIV infection. Health Services Research, 28, 543–561.Google Scholar
  17. Holzemer, W. L., Corless, I. B., Nokes, K. M., Turner, J. G., Brown, M. A., Powell-Cope, G. M., Inouye, J., Henry, S. B., Nicholas, P. K., and Portillo, C. J. (1999). Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care and STDS, 13, 185–197.Google Scholar
  18. Lederman, M. M., and Valdez, H. (2000). Immune restoration with antiretroviral therapies: Implications for clinical management. JAMA, 284, 223–228.Google Scholar
  19. Lin, H. J., Pedneault, L., and Hollinger, F. B. (1998). Intra-assay performance characteristics of five assays for quantification of human immunodeficiency virus type 1 RNA in plasma. Journal of Clinical Microbiology, 36, 835–839.Google Scholar
  20. Lucas, G. M., Chaisson, R. E., and Moore, R. D. (1999). Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Annals of Internal Medicine, 131, 81–87.Google Scholar
  21. Moore, J., Schuman, P., Schoenbaum, E., Boland, B., Solomon, L., and Smith, D. (1999). Severe adverse life events and depressive symptoms among women with or at risk for HIV infection in four cities in the United States of America. AIDS, 13, 2459–2468.Google Scholar
  22. Moore, R. D., and Chaisson, R. E. (1999). Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS, 13, 1933–1942.Google Scholar
  23. Moore, R. D., Stanton, D., Gopalan, R., and Chaisson, R. E. (1994). Racial differences in the use of drug therapy for HIV disease in an urban community. New England Journal of Medicine, 330, 763–768.Google Scholar
  24. Musselman, D. L., McDaniel, J. S., Porter, M. R., and Nemeroff, C. B. (1999). Screening for depression. Journal of the Medical Association of Georgia, 88, 47–53.Google Scholar
  25. Myers, J. K., and Weissman, M. M. (1980). Use of a self-report symptom scale to detect depression in a community sample. American Journal of Psychiatry, 137, 1081–1084.Google Scholar
  26. Myers, L. B., and Midence, K. (Eds.). (1998). Adherence to treatment in medical conditions. The Netherlands: Harwood Academic.Google Scholar
  27. Palella, F. J., Jr., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., and Holmberg, S. D. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. New England Journal of Medicine, 338, 853–860.Google Scholar
  28. Paterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., Squier, C., Wagener, M. M., and Singh, N. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133, 21–30.Google Scholar
  29. Radloff, L. S. (1977). The CES-D scale: A self-report depression scale for research in the general population. Applied Psychological Measurement, 1, 385–401.Google Scholar
  30. Roberts, K. J. (2000). Barriers to and facilitators of HIV-positive patients' adherence to antiretroviral treatment regimens. AIDS Patient Care and STDS, 14, 155–168.Google Scholar
  31. Roca, B., Gomez, C. J., and Arnedo, A. (2000). A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir, in treatment-experienced HIV-infected patients. AIDS, 14, 157–161.Google Scholar
  32. Samet, J. H., Libman, H., Steger, K. A., Dhawan, R. K., Chen, J., Shevitz, A. H., Dewees-Dunk, R., Levenson, S., Kufe, D., and Craven, D. E. (1992). Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: Across-sectional study in a municipal hospital clinic. American Journal of Medicine, 92, 495–502.Google Scholar
  33. SAS Institute. (1996). SAS statistical software (Release 6.12). Cary, NC: Author.Google Scholar
  34. Scott, J., Gilvarry, E., and Farrell, M. (1998). Managing anxiety and depression in alcohol and drug dependence. Addictive Behaviors, 23, 919–931.Google Scholar
  35. Shapiro, M. F., Morton, S. C., McCaffrey, D. F., Senterfitt, J. W., Fleishman, J. A., Perlman, J. F., Athey, L. A., Keesey, J. W., Goldman, D. P., Berry, S. H., and Bozzette, S. A. (1999). Variations in the care of HIV infected adults in the United States; results from the HIV Cost and Services Utilization Study. JAMA, 281, 2305–2315.Google Scholar
  36. Simon, G. E., Goldberg, D., Tiemens, B. G., and Ustun, T. B. (1999). Outcomes of recognized and unrecognized depression in an international primary care study. General Hospital Psychiatry, 21, 97–105.Google Scholar
  37. Singh, N., Berman, S. M., Swindells, S., Justis, J. C., Mohr, J. A., Squier, C., and Wagener, M. M. (1999). Adherence of HIV infected patients to antiretroviral therapy. Clinical Infectious Diseases, 29, 824–830.Google Scholar
  38. Singh, N., Squier, C., Sivek, C., Wagener, M., Nguyen, M. H., and Yu, V. L. (1996). Determinants of compliance with antiretroviral therapy in patients with HIV: Prospective assessment with implications for enhancing compliance. AIDS Care, 8, 261–269.Google Scholar
  39. Smith, D. K., Warren, D., Vlahov, D., Schuman, P., Stein, M. D., Greenberg, B. L., and Holmberg, S. D. (1997). Design and baseline participant characteristics of the HIV Epidemiology Research (HER) Study: A prospective cohort study of HIV infection in US women. American Journal of Epidemiology, 146, 459–469.Google Scholar
  40. Sorensen, J. L., Mascovich, A., Wall, T. L., DePhilippis, D., Batki, S. L., and Chesney, M. (1998). Medication adherence strategies for drug abusers with HIV/AIDS. AIDS Care, 10, 297–312.Google Scholar
  41. Stone, V. E., Clarke, J., Lovell, K., and Mayer, K. H. (1997, May). Protease inhibitor-related knowledge, attitudes and patterns of use by gender. Paper presented at the meeting of the National Conference of Women and HIV, Pasadena CA.Google Scholar
  42. Wainberg, M. A., and Friedland, G. (1998). Public health implications of antiretroviral therapy and HIV drug resistance. JAMA, 279, 2000–2002.Google Scholar
  43. Weissman, M. M., Sholomskas, D., Pottenger, M., Prusoff, B. A., and Locke, B. Z. (1977). Assessing depressive symptoms in five psychiatric populations:A validation study. American Journal of Epidemiology, 106, 203–214.Google Scholar

Copyright information

© Plenum Publishing Corporation 2001

Authors and Affiliations

  • Paula Schuman
    • 1
  • Suzanne E. Ohmit
    • 1
  • Mardge Cohen
    • 2
  • Henry S. Sacks
    • 3
  • Jean Richardson
    • 4
  • Mary Young
    • 5
  • Ellie Schoenbaum
    • 6
  • Anne Rompalo
    • 7
  • Lytt Gardner
    • 8
  1. 1.Wayne State UniversityDetroit
  2. 2.Cook County HospitalChicago
  3. 3.Mount Sinai Medical CenterNew York
  4. 4.University of Southern California/Norris Comprehensive Cancer CenterLos Angeles
  5. 5.Georgetown University Medical CenterWashington
  6. 6.Montefiore Medical CenterBronx
  7. 7.Johns Hopkins UniversityBaltimore
  8. 8.Centers for Disease Control and PreventionAtlanta

Personalised recommendations